Therapeutic preparation comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
1. A therapeutic preparation comprising insulin, the preparation shaped as a solid tissue penetrating member having a pointed end, the preparation configured to be contained in a swallowable enclosure having a tubular shape with curved ends and to be released from the enclosure to penetrate and be inserted into a gastro-intestinal (GI) wall of a patient after oral ingestion of the enclosure by the application of force upon the preparation, wherein upon insertion into the GI wall, the preparation releases insulin into the blood stream of the patient.
2. The preparation of claim 1 , wherein the preparation is adapted for insertion into a wall of the patient's small intestine.
3. The preparation of claim 1 , wherein the preparation is adapted for insertion into a wall of the patient's stomach.
4. The preparation of claim 1 , wherein the preparation is adapted to be operably coupled to a delivery means having a first configuration and a second configuration, the preparation being contained within the enclosure in the first configuration and advanced out of the enclosure and into the GI wall in the second configuration.
5. The preparation of claim 4 , wherein the delivery means comprises a least one expandable balloon having an expanded and a non-expanded state and the first configuration is the non-expanded state and the second configuration is the expanded state.
6. The preparation of claim 4 , wherein the delivery means comprises a spring.
7. The preparation of claim 1 , wherein the preparation comprises a biodegradable material which degrades within the intestinal wall to release insulin into the blood stream.
8. The preparation of claim 7 , wherein the biodegradable material comprises poly(lactic-co-glycolic acid) (PLGA), a sugar or maltose.
9. The preparation of claim 1 , wherein the preparation comprises at least one pharmaceutical excipient.
10. The preparation of claim 9 , wherein the at least one pharmaceutical excipient comprises at least one of a binder, a preservative or a disintegrant.
11. The preparation of claim 10 , wherein the binder comprises polyethylene glycol (PEG).
12. The preparation of claim 1 , wherein a weight percent of insulin in the tissue penetrating member comprises between about 2 to 15%.
13. The preparation of claim 1 , wherein a dose of insulin in the preparation is in a range from about 1 to 50 units of insulin.
14. The preparation of claim 13 wherein the dose of insulin is in a range from about 4 to 9 units of insulin.
15. The preparation of claim 1 , wherein the tissue penetrating member includes a retaining feature for retaining the tissue penetrating member within the GI wall after insertion.
16. The preparation of claim 1 , wherein the tissue penetrating member includes a shaped section in which the insulin is contained.
17. The preparation of claim 16 , wherein the shaped section has a cylinder or pellet shape.
18. The preparation of claim 1 , wherein the tissue penetrating member has sufficient stiffness to be advanced completely into the intestinal wall by the application of a force to the tissue penetrating member.
19. The preparation of claim 1 , wherein the enclosure comprises a capsule.
20. The preparation of claim 1 , wherein the preparation is configured to produce a long-term release of insulin.